Topotecan and paclitaxel in previously treated patients with relapsed small cell lung cancer: phase II trial of the North Central Cancer Treatment Group.
Dy
Grace K
GK
Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA. Dy.Grace@mayo.edu
Jett
James R
JR
Geoffroy
Francois J
FJ
Krewer
Keith D
KD
Tazelaar
Henry
H
Maurer
Matthew
M
Rowland
Kendrith
K
Mailliard
James
J
Krook
James
J
Dakhil
Shaker
S
Kutteh
Leila
L
Kugler
John
J
Wender
Donald
D
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000556:secondary; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000401:mortality; D018450:Disease Progression; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D009503:Neutropenia / Q000139:chemically induced; D017239:Paclitaxel / Q000008:administration & dosage* / Q000009:adverse effects; D015996:Survival Rate; D019772:Topotecan / Q000008:administration & dosage* / Q000009:adverse effects
D019772:Topotecan; D017239:Paclitaxel